Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s)
Publication
, Conference
Erba, HP; Kantarjian, HM; Claxton, DF; Arellano, M; Lyons, RM; Kovacsovics, TJ; Gabrilove, J; Eckert, S; Faderl, S
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2009
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Kantarjian, H. M., Claxton, D. F., Arellano, M., Lyons, R. M., Kovacsovics, T. J., … Faderl, S. (2009). Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 27). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Erba, H. P., H. M. Kantarjian, D. F. Claxton, M. Arellano, R. M. Lyons, T. J. Kovacsovics, J. Gabrilove, S. Eckert, and S. Faderl. “Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, et al. Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Erba, H. P., et al. “Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s).” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15, AMER SOC CLINICAL ONCOLOGY, 2009.
Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S. Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor (s). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
May 20, 2009
Volume
27
Issue
15
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
45th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences